FDG-PET/CT tracks response, guides biopsy in resistant GIST

Tuesday, December 1 | 4:30 p.m.-5:30 p.m. | T8-SSNMMI04-6 | Room S405  

F-18 FDG-PET/CT can monitor treatment response and direct biopsy toward metabolically active lesions in patients with gastrointestinal stromal tumors (GIST) that have stopped responding to standard therapy, researchers will report in this session. 

Presenter Anthony Arcese, MD, of Brigham and Women’s Hospital in Boston, and colleagues enrolled 10 patients with tyrosine kinase inhibitor (TKI)-refractory GIST in a phase II trial evaluating the novel TKI combination bezuclastinib and sunitinib. Each patient underwent three sequential F-18 FDG-PET/CT scans: a baseline after TKI washout, a second after two weeks of bezuclastinib alone, and a third scan two weeks after adding sunitinib. Quantitative metrics across 30 total PET/CT examinations included mean standard uptake value (SUVmean), total tumor activity, and total tumor volume. 

SUVmean showed the most consistent decline, falling from a median of 6.1 at baseline to 4.5 after bezuclastinib alone and to 3.6 after combination therapy (p < 0.001). Median total tumor activity dropped significantly as well, from 2,677.1 to 2,087.9 to 716.5 (p = 0.025). Total tumor volume declined in most patients but did not reach statistical significance. At the third scan, persistent FDG-avid lesions were flagged and prioritized for image-guided biopsy. 

GISTs can develop heterogeneous KIT resistance mutations during TKI therapy, producing variable drug sensitivity across individual lesions, a distinction that conventional anatomic imaging alone has struggled to characterize, the researchers noted. 

"These findings support PET/CT as a bridge between imaging response assessment and precision oncology, enabling biopsy of metabolically active lesions to evaluate potential resistance mutations," Arcese and colleagues noted. 

Attend this session to learn more. 

Page 1 of 2
Next Page